The

Promise of

Interleukin-2

Therapy.

14-17 Sept. 2022

For autoimmune and inflammatory diseases, allergy, transplantation and cancer

Centre international de Conférences Sorbonne Université

4 place Jussieu - Patio 44-55

75005 - Paris, France

*To submit before June 30th.2022
ANR.png
logoimap.png
logosorbonne.png
logoAPHP.png
logoinserm.png

Confirmed Speakers

(by alphabetical order)

Abul K. Abbas, Stanley Appel, Christophe Benoist, Jeff Bluestone, Onur Boyman, Frederic de Blay, Jason Fontenot, Ron Germain, Agnes Hartemann, Jens Humrich, John Koreth, David Klatzmann, Emmanuelle Le Chatelier, Warren Leonard, Matteo Levisetti, Zhanguo Li, Adrian Liston, Catherine Lubetzki, Ziad Mallat, Diane Mathis, Arsene Mekinian, Thomas Malek, Steven Quayle, Aleksander Rudensky, Shimon Sakaguchi, Scott Snapper, Mary Struthers, Nadia Tchao, Georges Tsokos, Thomas Vazquez, Lucy Walker, Jonathan Zalevsky

 

Friday 16th

9.00 am

Session V
Treg targeted IL-2 muteins in clinical trials
Chair : J. Humrich
 
1. Insights From Engineering IL-2 Muteins: Results from a Phase 1b Study in Systemic Lupus
Erythematosus (SLE)
. Nadia Tchao / Amgen

2. Update on the Ongoing Development of Rezpegaldesleukin, a Selective Regulatory T-Cell Inducing IL-2 Conjugate. Jonathan Zalevsky / Nektar

3. IL2-CD25 for selective Treg expansion. Mary Struthers / Bristol Myers Squibb

11.00 am

Session VI
Biomarkers of IL-2 therapeutic effects: iMAP outcomes
Chair : C. Benoist
 
1. Deep cytometry. Michelle Rosenzwajg, 24'.

2. Transcriptome. Nicolas Tchitcheck, 25'.

3. TCR.  Encarnita Mariotti-Ferrandiz, 25'.

4. Microbiome. Emmanuelle Le Chatelier, 25'.
 
5. Comments and discussion. Christophe Benoist, 15'.

10.30-11.00 am
Coffee Break

1.00 pm

Lunch

2.00 pm

4.00 pm

Session VII
IL-2 and Treg cell therapies: competing or complementing?
Chair : O.Boyer
 
1. Advances in Engineered Regulatory T cell Therapies. Jason Fontenot, Sangamo

2. Suppressing Neuroinflammation: Treg Therapy of ALS. Stanley Appel / Coya Tx.


Talks from abstract
- Finely controlled IL2 signal in engineered human Tregs with utilizing a chemically induced signalling
complex.
Thomas Wickhman, GentiBio

- Remarkably enhanced survival and superior efficacy of IL-2 self-sufficient Tregs. Janie Robert

Session VIII
Round table: The promise of IL-2 and IL-2 muteins in autoimmune and inflammatory diseases
Moderator and introductory talk:
Abul Abbas


- N. Tchao
- J. Zalevsky
-  D. Klatzmann
- J. Humrich
- S. Snapper
- T. Malek

3.30 - 4.00 pm
Coffee Break

5.30 pm

Drinks and posters

7.00 pm

End of the day